ライフサイエンスコーパス: plasma concentration

1 ysis (HD) due to their low free (dialyzable) plasma concentration.

2 on of erlotinib, without affecting erlotinib plasma concentration.

3 llection for laboratory tests and mavacamten plasma concentration.

4 yme assays, and measures of serotonin (5-HT) plasma concentration.

5 system without essentially increasing their plasma concentrations.

6 s experienced potentially toxic piperacillin plasma concentrations.

7 with i.v. delivery with substantially lower plasma concentrations.

8 ction of clearance was driven by rifapentine plasma concentrations.

9 quotients were determined using trough INSTI plasma concentrations.

10 asing fatty acid chain length and the target plasma concentrations (0.5-1.0ng/mL over a month-long pe

11 49327 (30 mg/kg/day, yielding unbound trough plasma concentration ~180 nM) improves left heart functi

12 up displayed marked increases in DHA and EPA plasma concentrations (2.6- and 3.5-fold), as well as de

13 on DPV use in reproductive-age women (median plasma concentration: 264 pg/mL).

14 nd a pharmacokinetics study documents a peak plasma concentration 30 min after dosing, with the agent

15 NM3RPV treatment led to RPV plasma concentrations above the protein-adjusted 90% inh

16 bjective experience, brain activity and drug plasma concentrations across time.

17 mine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK

18 In addition, a broad range of plasma concentrations after oral dosing resulted from sm

19 were statistically significant predictors of plasma concentrations among individuals who consumed [Fo

20 n had minimal impact on DRV maximum observed plasma concentration and area under the curve; DRV Ctrou

21 linear relationship between total dabigatran plasma concentration and diluted thrombin time and ecari

22 Unbound piperacillin plasma concentration and fractional time of plasma conce

23 Vandetanib plasma concentration and tumor growth at US were evaluat

24 to mavacamten were decreased LVEF at higher plasma concentrations and atrial fibrillation.

25 reatment was well-tolerated, achieved target plasma concentrations and demonstrated near-complete sta

26 ary of RPV prodrugs designed to sustain drug plasma concentrations and improved tissue biodistributio

27 Splenic Th9 and Th17 cells, plasma concentrations and liver expression of IL-9 and I

28 ester, transfer across the placenta (121% of plasma concentrations) and into breastmilk (3% of plasma

29 circulating ghrelin levels, increased GLP-1 plasma concentration, and remodeling of gut microbiome d

30 However, in our study isradipine plasma concentrations approved for therapy were not neur

31 Soluble thrombomodulin plasma concentrations are elevated in steroid-resistant

32 Interindividual differences in resulting plasma concentrations are low.

33 that accounted well for the time profiles of plasma concentrations as well as effects on tremor sever

34 We measured piperaquine plasma concentrations at baseline, 7 days, and day of re

35 imal schedule because of the highest maximum plasma concentration being reached.

36 ND)) and binding potential relative to total plasma concentration (BP(P)) were derived using an arter

37 fenamide is a prodrug that reduces tenofovir plasma concentrations by 90% compared with tenofovir dis

38 vel tenofovir prodrug that reduces tenofovir plasma concentrations by 90%, thereby decreasing off-tar

39 We tested vitamin B-12 plasma concentrations by using chemiluminescent competit

40 ed in a significant increase in mean maximum plasma concentration (C max ), elimination half-life and

41 ction on dose-normalised deferasirox minimum plasma concentration (C(min)).

42 l cells are a major source of PTX3, and PTX3 plasma concentration can serve as an independent strong

43 Maximum plasma concentration (Cmax) and area under the concentra

44 of the study through a comparison of maximum plasma concentration (Cmax) and area under the concentra

45 o free lutein, PLGA-NP increased the maximal plasma concentration (Cmax) and area under the time-conc

46 The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL an

47 on versus time curve (AUC), maximum observed plasma concentration (Cmax), and time above a threshold

48 c mean ratio (GMR) PK2/PK1 of EFV400 maximum plasma concentration (Cmax), area under the curve (AUC),

49 ed using peptide doses that produced maximal plasma concentrations (Cmax) of less than 1% of RTD-1 le

50 id (63% and 70% lower geometric mean maximum plasma concentration [Cmax] and 77% and 82% lower AUC0-t

51 ion modeling, the egg intervention increased plasma concentrations compared with control by the follo

52 esulting in nine- and 18-fold higher maximum plasma concentrations compared with standard dose, respe

53 -compartment toxicokinetic model to estimate plasma concentrations corresponding to tap water intake

54 a concentrations) and into breastmilk (3% of plasma concentrations), coupled with slower elimination,

55 peaked before d6-alpha-T in 77 of 80 paired plasma concentration curves.

56 d from 1.15% to 9.48% of the variance in the plasma concentration data.

57 In women (n = 12), motilin (P = 0.04) plasma concentrations decreased after intragastric DB ad

58 Plasma concentrations decreased over time for perfluorod

59 Pilot studies showed lower tenofovir plasma concentrations during PrEP use among transgender

60 s showed that high-dose methotrexate maximum plasma concentration (estimate = 0; P = .48), median cle

61 en though the compounds reached steady state plasma concentrations exceeding their Ki values by >60-f

62 portant biomarker of heart failure where low plasma concentrations exclude cardiac dysfunction.

63 who are at the highest risk of unpredictable plasma concentration exposing them to overdose, toxicity

64 avenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap t

65 avenous colistin is difficult to use because plasma concentrations for antibacterial effect overlap t

66 ood containing the peak, midpoint, or trough plasma concentrations for meropenem, ceftolozane-tazobac

67 s within 90-106% of validated NIST reference plasma concentrations for the panel of measured amino ac

68 from multiple assays of clozapine metabolite plasma concentrations from a clozapine monitoring servic

69 tegrate multiple drugs and provide sustained plasma concentrations from several weeks to up to one ye

70 pancy on whole blood B cells was observed at plasma concentrations >0.3-0.4 ug/mL.

71 e contractility assays over paroxetine and a plasma concentration higher than its IC50 for over 7 h.

72 rvoirs candidate patches achieved esketamine plasma concentrations higher than the target concentrati

73 interdigestive motility, motilin and ghrelin plasma concentrations, hunger and satiety ratings, and f

74 PC-4 cell proliferation and displayed higher plasma concentration in mice than lead compound 1.

75 , giving the conversion formula: (creatinine plasma concentration in mumol/L) = (creatinine concentra

76 Ss) to discover genetic markers of clozapine plasma concentrations in a large sample of patients with

77 helial lining fluid is greater than/equal to plasma concentrations in healthy adults.

78 f CD4-CCR5-VLP produced only subneutralizing plasma concentrations in HIV-1-infected humanized mice b

79 corroborated by increased insulin and IGF-1 plasma concentrations in multiple system atrophy patient

80 tose 1-phosphate (0.1 mM), (corresponding to plasma concentrations in patients on galactose-restricte

81 Mean plasma concentrations in rats, 24 h post-application of

82 ral bioavailability (F = 50%) and sufficient plasma concentrations in rats, providing an excellent st

83 We report here PFAA plasma concentrations in wild populations of great tits

84 Pimodivir plasma concentrations increased in a dose-proportional m

85 The unlabeled drug dose and plasma concentration leading to a 50% reduction of (11)C

86 We modeled protein plasma concentration (log10 of relative fluorescence uni

87 proach in the Discovery Cohort: each protein plasma concentration (log10 of RFU) was modeled as the e

88 rial blood samples over 24 hours for iohexol plasma concentration measurements.

89 ic and epigenetic loci associated with their plasma concentrations (n = 750 healthy older adults).

90 The highest plasma concentration observed (for fish exposed to 25 mu

91 pendent increases in decitabine AUC and peak plasma concentration occurred with each cohort dose esca

92 to note that the area under the curve of the plasma concentration of (-)-epicatechin metabolites over

93 ich the methylxanthines mediate an increased plasma concentration of (-)-epicatechin metabolites that

94 e implants generated an average cabotegravir plasma concentration of 373 ng/ml in rhesus macaques.

95 Samples were collected for plasma concentration of AEA, PEA, OEA, and JNJ-42165279.

96 The primary outcome was the maximum plasma concentration of avobenzone over days 1 through 2

97 The primary outcome was the maximum plasma concentration of avobenzone.

98 Body composition, plasma concentration of beta-hydroxybutyrate (beta-HB) a

99 The mean +/- SD plasma concentration of betaine was 13.2 +/- 2.7 mumol/L

100 The median, average, steady-state plasma concentration of colistin (Css,avg) was 0.88 mg/L

101 ng of the patient factors that influence the plasma concentration of colistin, and assess the likely

102 Finally, plasma concentration of Dkk-1, an antagonist of canonica

103 The maximum plasma concentration of each drug was determined at mont

104 In mice not treated with exogenous tPA, the plasma concentration of endogenous tPA increased 3-fold

105 The primary outcome was the plasma concentration of etonogestrel and ethinylestradio

106 In critically ill patients, plasma concentration of ghrelin significantly differs fr

107 After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein

108 olymorphism has been associated with a lower plasma concentration of holotranscobalamin.

109 This influenced plasma concentration of inflammatory cytokines and key m

110 tween the change in driving pressure and the plasma concentration of interleukin-6, soluble receptor

111 An elevated plasma concentration of lipopolysaccharide (LPS) caused

112 The total plasma concentration of measured amino acids was signifi

113 A higher plasma concentration of methotrexate was associated with

114 XR-knockout mice on a high-protein diet, the plasma concentration of newly formed urea was significan

115 ronger among nonsmokers and those with lower plasma concentration of pyridoxal-5'-phosphate (P-intera

116 nship between the brain target occupancy and plasma concentration of the drug.

117 found higher in HS rats despite no change in plasma concentration of these ions.

118 Lastly, the plasma concentration of TSP-1 is significantly increased

119 mice, the addition of elacridar (at systemic plasma concentrations of >/=200 ng/mL) resulted in an in

120 Plasma concentrations of 200 proteins changed significan

121 We measured baseline fasting plasma concentrations of 23 metals and used conditional

122 We here determined arterial plasma concentrations of 25 different cytokines, growth

123 Plasma concentrations of 4 formate precursors (serine, g

124 Decreased baseline plasma concentrations of 5 of 266 evaluable proteins (an

125 a standardized breakfast was consumed, with plasma concentrations of acylated ghrelin, glucagon-like

126 To test this, we measured plasma concentrations of albumin, total proteins.

127 Geometric mean maximum plasma concentrations of all 6 active ingredients were g

128 mino acid supplementation altered uptake and plasma concentrations of all the essential amino acids.

129 Plasma concentrations of amino acids (AAs), in particula

130 gininemia in severe malaria, we measured the plasma concentrations of amino acids involved in de novo

131 arial dosing strategy as for human patients, plasma concentrations of amodiaquine in healthy animals

132 res: apolipoprotein E allele carrier status; plasma concentrations of amyloid beta peptides 1-42 and

133 Here we quantify plasma concentrations of an N-terminal fragment of tau (

134 xamined associations of baseline (1993-1997) plasma concentrations of apoC-III and subspecies of HDL

135 Plasma concentrations of BDE-153 and beta-HCH did not si

136 Plasma concentrations of BDNF were significantly affecte

137 Plasma concentrations of biologically active oxylipins d

138 introduced early in complementary feeding on plasma concentrations of biomarkers in choline pathways,

139 ystemic inflammation, reflected by increased plasma concentrations of C-reactive protein (CRP) and fi

140 als (CIs) comparing the extreme quartiles of plasma concentrations of C16:0, C22:0, C24:0, and C24:1

141 These findings suggest that plasma concentrations of catalytic iron and hepcidin may

142 Higher plasma concentrations of catalytic iron and lower concen

143 ed and multivariable adjusted models, higher plasma concentrations of catalytic iron were associated

144 chemiluminescent competitive immunoassay and plasma concentrations of choline, betaine, dimethylglyci

145 Differential plasma concentrations of circulating lipid species are a

146 CRRT patients (n = 31) had lower plasma concentrations of citrulline, glutamic acid and c

147 Plasma concentrations of cleaved high-molecular-weight k

148 Plasma concentrations of colistimethate and formed colis

149 Plasma concentrations of collagen type 1 cross-linked C-

150 receptor occupancy was assessed at different plasma concentrations of CP101,606, a GluN2B receptor an

151 The obtained conversion factors of DBS to plasma concentrations of dabigatran, apixaban, and rivar

152 Plasma concentrations of dicarbonyls methylglyoxal (MGO)

153 Peak plasma concentrations of elamipretide occurred at end-in

154 EPA supplementation increased plasma concentrations of EPA and docosapentaenoic acid (

155 Transpulmonary thermodilution-based EVLWi, plasma concentrations of epithelial (soluble receptor fo

156 CSF and total plasma concentrations of EVG, TDF, TAF, tenofovir (TFV),

157 hydrogel nucleation and growth at near human plasma concentrations of fibrinogen.

158 Despite standard weight-based dosing, peak plasma concentrations of first-line drugs were below the

159 ere assessed for their association with cord plasma concentrations of formate.

160 008) with measured first pregnancy trimester plasma concentrations of four PFASs (in nanograms/millil

161 Plasma concentrations of free choline, betaine, and phos

162 Fasting and postprandial plasma concentrations of glucose and insulin were analyz

163 The plasma concentrations of glutamine, glutamate, proline,

164 Plasma concentrations of glycosylphosphatidylinositol (G

165 Plasma concentrations of glyoxal are elevated in in diab

166 High plasma concentrations of homocysteine are assumed to be

167 of 15-yr-old children (n= 324), we measured plasma concentrations of homocysteine, choline, and beta

168 led immunization-associated increases in the plasma concentrations of immunomodulatory cytokines and

169 r regression to examine associations between plasma concentrations of individual PFASs and aBMD z-sco

170 KYN pathway analytes-including plasma concentrations of indoleamine 2,3-dioxygenase (ID

171 In septic patients, plasma concentrations of interleukin (IL)-1alpha and IL-

172 p=0.0078) based on a single variant, as did plasma concentrations of interleukin-6 receptor subunit

173 Plasma concentrations of ketamine, norketamine, and HNKs

174 Increased plasma concentrations of lipoprotein(a) (Lp(a)) are asso

175 otoxic events were accompanied by changes in plasma concentrations of macrophage-derived cytokine, eo

176 Plasma concentrations of markers of endothelial (angiopo

177 ty was evaluated using clinical outcomes and plasma concentrations of markers of inflammation, glucos

178 h ophthalmic issues had significantly higher plasma concentrations of metabolites that are associated

179 Elevated serum and plasma concentrations of MMP-8 are associated with the r

180 Plasma concentrations of MMP3 and MMP7 were elevated in

181 Plasma concentrations of N- terminal pro-B-type natriure

182 Plasma concentrations of natriuretic peptides decline wi

183 ction fraction </=40%, dyspnea, and elevated plasma concentrations of natriuretic peptides were rando

184 r congestion on chest radiography, increased plasma concentrations of natriuretic peptides, mild-to-m

185 hospitalized for AHF with dyspnea, increased plasma concentrations of natriuretic peptides, systolic

186 Plasma concentrations of NDEs, assessed by counts and le

187 inhibition of fractional DNL associated with plasma concentrations of NDI-010976 >4 ng/mL.

188 The plasma concentrations of nerve growth factor (BCAA: 4.0

189 igh-risk individuals, we quantified baseline plasma concentrations of nine PFAS among 957 participant

190 type 2 diabetes is inversely correlated with plasma concentrations of odd-chain fatty acids [OCFAs; p

191 gatively correlated with AT pO2, whereas the plasma concentrations of other cytokines and chemokines

192 Secondary outcomes were the maximum plasma concentrations of oxybenzone, octocrylene, and ec

193 Secondary outcomes were the maximum plasma concentrations of oxybenzone, octocrylene, homosa

194 Temporal trends in plasma concentrations of per- and polyfluoroalkyl substa

195 A quantitative test for plasma concentrations of PfHRP2 could be useful in ident

196 sing linear regression, children with higher plasma concentrations of PFOA, PFOS, and perfluorodecano

197 uperior in vivo performance, delivering high plasma concentrations of PIB in PK studies conducted in

198 que, and parasite biomass was estimated from plasma concentrations of Plasmodium falciparum histidine

199 Notably, the HSV vector induced elevated plasma concentrations of polarizing cytokines and chemot

200 We hypothesized that high plasma concentrations of POPs in Asian Indian migrants a

201 OSPW-OF exposure also did not affect plasma concentrations of pregnancy-associated hormones o

202 and insulin-resistant subjects have elevated plasma concentrations of pro-NT, and in longitudinal stu

203 ain effect of trajectory class membership on plasma concentrations of proinflammatory tumor necrosis

204 aimed to measure and validate differences in plasma concentrations of proteins that are associated wi

205 Increased plasma concentrations of PTX3 were detected in 96 patien

206 Low plasma concentrations of pyridoxal 5'-phosphate (PLP) ar

207 learning analysis demonstrates that baseline plasma concentrations of resolvin D4, 10S, 17S-dihydroxy

208 Plasma concentrations of serotonin, taurine, and glycero

209 The plasma concentrations of several biomarkers are either p

210 We quantified plasma concentrations of several PFASs and measured area

211 e (TSH) and free thyroxine (fT4) levels with plasma concentrations of six PFAS chemicals in the first

212 gement had lower lung function and decreased plasma concentrations of soluble CD40L (376 pg/ml vs. 50

213 tion (WHO) BMD categories at both sites, and plasma concentrations of soluble receptor activator of n

214 Elevated plasma concentrations of soluble VEGFA isoforms are asso

215 Plasma concentrations of sRAGE (soluble receptor for adv

216 Plasma concentrations of summed polychlorinated biphenyl

217 The plasma concentrations of tanshinones were detected by a

218 Plasma concentrations of the CCR10 ligand CCL27 are sign

219 a highly sensitive IL-2 assay, the observed plasma concentrations of the drug at 90 min exceeded the

220 Elevated plasma concentrations of the gut bacteria choline metabo

221 ttle visible evidence of use, and maintained plasma concentrations of the hormone above the human the

222 release was achieved via NIR laser light and plasma concentrations of the model drug were determined

223 The 9 h DLI group, when both tumor and plasma concentrations of the prodrug were sufficient, sh

224 Higher plasma concentrations of the vitamin B-6 marker pyridoxa

225 Plasma concentrations of TMAO and its precursors were me

226 rotein (HDL), low-density lipoprotein (LDL), plasma concentrations of total cholesterol (TC) and trig

227 At baseline E4 carriers had higher plasma concentrations of total cholesterol (TC), low-den

228 ween the dose of quercetin-3-O-glucoside and plasma concentrations of total quercetin (R(2) = 0.52, P

229 Plasma concentrations of total-tau, NfL, amyloid-beta40

230 Plasma concentrations of triglycerides were measured imm

231 Plasma concentrations of triglycerides, nonesterified fa

232 Plasma concentrations of trimethylamine, TMAO, choline,

233 ence of arrhythmias was associated with high plasma concentrations of troponin-T and N-terminal brain

234 Increasing plasma concentrations of TVB-2640 were associated with p

235 or ritonavir-boosted atazanavir would alter plasma concentrations of vaginally administered etonoges

236 Plasma concentrations of VEGF-A, VEGF-C, Ang1, and Ang2

237 k syndrome and sepsis), we sought to analyze plasma concentrations of VEGFs and Angs in patients with

238 hospitals in London, UK, and measured serial plasma concentrations of vitamin B(1), B(6), B(12), C an

239 Serum and plasma concentrations of vitamin B-12, holotranscobalami

240 peripheral neuropathy in elders with normal plasma concentrations of vitamin B-12.

241 d cediranib area under the curve and maximum plasma concentration on the daily, but not intermittent,

242 treatment was increased, with higher median plasma concentrations on day 7 (5.88 versus 2.67 mug/mL)

243 cally significant difference in piperacillin plasma concentrations over time between groups.

244 MCAM plasma concentrations peaked 15-45 min after injection,

245 At the decitabine 0.16 mg/kg dose, plasma concentrations peaked at approximately 50 nM (Cma

246 Naloxone plasma concentrations peaked at ~20 min post naloxone, a

247 e (using a dose that reproduced stress-level plasma concentrations) potentiated cocaine-primed reinst

248 ld male R92Q mice, ranolazine at therapeutic plasma concentrations prevented the development of HCM-r

249 Brain-to-plasma concentration ratio of [(13)C(5)]-5-formylTHF was

250 (range, n = 5) rilpivirine cord-to-maternal plasma concentration ratio was 0.50 (range, .35-.81).

251 OM exerted plasma concentration-related increases in left ventricul

252 cies of circulating CCR10(+) ILC2s and CCL27 plasma concentrations represent candidate markers of ast

253 lity and hunger ratings, motilin and ghrelin plasma concentrations, satiety, and caloric intake.Women

254 at BUP, NBUP, and MET at clinically relevant plasma concentrations significantly induced BCRP mRNA up

255 ar mutant alpha-synuclein in mouse brains at plasma concentrations similar to those that would be see

256 plasma concentration and fractional time of plasma concentration spent over 64 mg/L (4-fold the mini

257 entricular volumes that correlated with peak plasma concentrations, supporting a temporal association

258 In part 1, ABI-H0731 reached maximum plasma concentrations (T(max)) in 2.50-4.17 h; the mean

259 ovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fuma

260 ens under maximal use conditions resulted in plasma concentrations that exceeded the threshold establ

261 spects of the use of these low doses and low plasma concentrations that require special attention.

262 mulations were systemically absorbed and had plasma concentrations that surpassed the FDA threshold f

263 Despite achieving plasma concentrations that were able to neutralize tier

264 lation to therapeutically relevant doses and plasma concentrations, there are specific aspects of the

265 rowth in comparison to 5-FU while area-under plasma concentration-time curve (AUC) of 5FU-SLN(4) was

266 platin continuous infusion of area under the plasma concentration-time curve 4.1 mg/mL per min per da

267 ighest doses for cohorts 1-3 (area under the plasma concentration-time curve from time of administrat

268 Plasma concentration-time data from 214 adult critically

269 Methods: Plasma concentration-time data from 214 adult critically

270 Steady-state 24 h dolutegravir plasma concentration-time pharmacokinetic profiling was

271 icals and their metabolites to reach maximal plasma concentrations (Tmax) should be synchronised with

272 BUP-XR provides sustained buprenorphine plasma concentrations to block drug-liking of abused opi

273 onsteroidal anti-inflammatory drugs but with plasma concentrations too low to disrupt PG biosynthesis

274 We hypothesized that plasma concentration variability would expose the critic

275 At week 24, median TAF plasma concentration was 11.05 ng/mL (2 hours post-dose,

276 At week 24, median TAF plasma concentration was 11.05 ng/mL (range, 2.84-147.1

277 Simulated median (interquartile range) day 7 plasma concentration was 29.4 (19.3-44.3) ng/ml in small

278 Results Vandetanib plasma concentration was lower with VERBs than with VS (

279 Piperacillin plasma concentration was measured every 12 hours over a

280 /PD) analysis in patients with isavuconazole plasma concentrations was conducted to establish the exp

281 s cerebral distribution and association with plasma concentrations, we used (7)Li magnetic resonance

282 Geometric mean trough plasma concentrations were 0.302 mug/mL (95% CI 0.237-0.

283 For avobenzone, geometric mean maximum plasma concentrations were 4.0 ng/mL (coefficient of var

284 For avobenzone, the overall maximum plasma concentrations were 7.1 ng/mL (coefficient of var

285 mong adults with the metabolic syndrome, PAB plasma concentrations were associated with fasting insul

286 While plasma concentrations were below therapeutic monitoring

287 Plasma concentrations were comparable to published data

288 were reported in phase 1, and pembrolizumab plasma concentrations were consistent with those previou

289 FKBPL plasma concentrations were increased in the presence of

290 Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations were measured after last DCB deplo

291 (C-reactive protein) and IL (interleukin)-6 plasma concentrations were measured immediately after su

292 MYDGF plasma concentrations were not affected by either storag

293 Child PFAS plasma concentrations were not associated with leptin or

294 Prenatal PFAS plasma concentrations were not associated with leptin, a

295 The highest PFAS plasma concentrations were of perfluorooctanesulfonic ac

296 Individual plasma concentrations were pooled, and nonlinear mixed-e

297 % differences between predicted and measured plasma concentrations were within a bias of +/-20%.

298 edian contributions of tap water to measured plasma concentrations were: PFOA 12% (95% probability in

299 he temporal profile of ghrelin or peptide YY plasma concentration with bedside functional assessment

300 avir using a dosing regimen that resulted in plasma concentrations within the therapeutic range for c